D. Carreon

Classification of types of tardive dyskinesia in a developmentally disabled population at a public residential facility

J. Swanson, S. Potkin, T. Wigal, 1993 .

Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.

S. Potkin, S. Potkin, Y. Jin, 1994, The Journal of clinical psychiatry.

The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments.

Robert E Black, Mark A. Miller, Gagandeep Kang, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

S‐adenosylmethionine blood levels in major depression: changes with drug treatment

S. Potkin, K. Bell, L. Plon, 1994, Acta neurologica Scandinavica. Supplementum.

D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine

M Masellis, S. Potkin, W. Bunney, 2003, Molecular Psychiatry.

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

S. Potkin, J. Wu, J. Fallon, 2001, The international journal of neuropsychopharmacology.

Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability.

S. Potkin, G. Alva, A. Kalali, 2002, Clinical therapeutics.

Measuring the psychological construct of control. Discriminant, divergent, and incremental validity of the Shapiro Control Inventory and Rotter's and Wallstons' Locus of Control Scales.

S. Potkin, D. Shapiro, B. Brown, 1993, International journal of psychosomatics : official publication of the International Psychosomatics Institute.

Tardive dyskinesia in a developmentally disabled population: Manifestation during the initial stage of a minimal effective dose program.

J. Swanson, S. Potkin, T. Wigal, 1996 .